-
1 Comment
XTL Biopharmaceuticals Ltd is currently in a long term uptrend where the price is trading 16.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
XTL Biopharmaceuticals Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 118.5% to $205K since the same quarter in the previous year.
Based on the above factors, XTL Biopharmaceuticals Ltd gets an overall score of 3/5.
| ISIN | US98386D3070 |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 11M |
|---|---|
| PE Ratio | None |
| Target Price | 30 |
| Beta | 1.01 |
| Dividend Yield | None |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for XTLB using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
